The cell and gene therapy (CGT) landscape has evolved dramatically over the past decade. With over 3,000 clinical trials worldwide and commercial therapies reaching patients at unprecedented speed, the industry faces a critical challenge orchestrating increasingly complex supply chains that span continents and involve multiple stakeholders. Unlike traditional pharmaceuticals manufactured in standardized batches, cell therapies follow a personalized model where each treatment is unique to one patient. This fundamental difference creates cellular orchestration challenges that traditional supply chain management approaches simply cannot address. The Complexity Challenge in Cell Therapy Supply Chains Cell therapy supply chains operate fundamentally differently from conventional …